Maze Therapeutics, Inc. (MAZE) Financial Ratios
4 years of historical data (2022–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
2.92
↓-42% vs avg
5yr avg: 5.02
30Y Low5.0·High5.0
ROE
↑
-47.5%
↓+35% vs avg
5yr avg: -72.6%
30Y Low-180%·High50%
Debt/EBITDA
N/A
—
5yr avg: 0.44
30Y Low0.4·High0.4
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
MAZE Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Maze Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Market Cap | $1.3B | $1.8B | — | — | — |
| Enterprise Value | $1.2B | $1.6B | — | — | — |
| P/E Ratio → | -7.90 | — | — | — | — |
| P/S Ratio | — | — | — | — | — |
| P/B Ratio | 2.92 | 5.02 | — | — | — |
| P/FCF | — | — | — | — | — |
| P/OCF | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
MAZE EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — |
| EV / FCF | — | — | — | — | — |
MAZE Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -47.5% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Gross Margin | — | — | 100.0% | — | — |
| Operating Margin | — | — | 34.4% | — | — |
| Net Profit Margin | — | — | 31.2% | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| ROE | -47.5% | -47.5% | 50.5% | -180.1% | -113.3% |
| ROA | -41.1% | -41.1% | 33.5% | -90.7% | -76.6% |
| ROIC | -99.4% | -99.4% | 150.9% | -230.6% | — |
| ROCE | -48.1% | -48.1% | 41.9% | -106.9% | -86.0% |
MAZE Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $189M exceeds total debt of $23M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Debt / Equity | 0.07 | 0.07 | 0.14 | 4.94 | 0.32 |
| Debt / EBITDA | — | — | 0.44 | — | — |
| Net Debt / Equity | — | -0.47 | -0.86 | 2.04 | -0.67 |
| Net Debt / EBITDA | — | — | -2.80 | — | — |
| Debt / FCF | — | — | -2.27 | — | — |
| Interest Coverage | — | — | — | — | — |
Net cash position: cash ($189M) exceeds total debt ($23M)
MAZE Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Maze Therapeutics, Inc.'s current ratio of 15.50x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 2.09x to 15.50x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Current Ratio | 15.50 | 15.50 | 9.76 | 2.09 | 5.11 |
| Quick Ratio | 15.50 | 15.50 | 9.76 | 2.09 | 5.11 |
| Cash Ratio | 15.16 | 15.16 | 9.52 | 1.79 | 4.81 |
| Asset Turnover | — | — | 0.70 | — | — |
| Inventory Turnover | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — |
MAZE Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Maze Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — |
| FCF Yield | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $43M | $44M | $44M | $44M |
Peer Comparison
Compare MAZE with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 MAZEYou | $1B | -7.9 | — | — | — | — | -47.5% | -99.4% | — |
 RARE | $2B | -4.1 | — | — | 83.8% | -79.5% | -607.5% | -89.4% | — |
 FOLD | $5B | -164.8 | 114.9 | 152.4 | 87.3% | 5.4% | -11.6% | 5.3% | 11.5 |
 ACMR | $6B | 66.9 | 44.6 | — | 44.4% | 12.1% | 6.2% | 7.0% | 2.4 |
 BEAM | $3B | -36.3 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 NTLA | $1B | -3.2 | — | — | 76.5% | -651.7% | -53.5% | -44.0% | — |
 ARWR | $10B | -6099.2 | 86.9 | 66.8 | 100.0% | 11.9% | -0.5% | 9.3% | 3.0 |
 ALNY | $39B | 124.2 | 68.6 | 83.0 | 81.8% | 13.5% | 73.3% | 33.4% | 2.3 |
 IONS | $12B | -31.0 | — | — | 98.3% | -40.5% | -70.7% | -12.8% | — |
 KRYS | $9B | 47.0 | 53.6 | 50.2 | 92.6% | 41.5% | 18.9% | 18.0% | 0.1 |
 PTCT | $6B | 9.6 | 6.4 | 8.8 | 95.9% | 49.5% | — | — | 0.5 |
| Healthcare Median | — | 23.1 | 14.4 | 19.0 | 64.0% | -4.2% | -32.6% | -11.2% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 4 years · Updated daily
What if you invested $1,000 in MAZE 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in MAZE be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs MAZE Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationMAZE vs RARE — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Ultragenyx Pharmaceutical Inc..
Compare NowMAZE — Frequently Asked Questions
Quick answers to the most common questions about buying MAZE stock.
What is Maze Therapeutics, Inc.'s P/E ratio?
Maze Therapeutics, Inc.'s current P/E ratio is -7.9x. This places it at the 50th percentile of its historical range.
What is Maze Therapeutics, Inc.'s ROE?
Maze Therapeutics, Inc.'s return on equity (ROE) is -47.5%. The historical average is -72.6%.
Is MAZE stock overvalued?
Based on historical data, Maze Therapeutics, Inc. is trading at a P/E of -7.9x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.